Elevar Therapeutics
Manufacturing · Utah, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2755 E Cottonwood Pkwy Ste 540, Salt Lak...Phone Number
(801) 303-7440Website
www.elevartherapeutics.comRevenue
$19.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Elevar Therapeutics
Elevar Therapeutics is a biopharmaceutical company dedicated to developing oncology therapeutics aimed at improving treatment experiences and outcomes for patients with limited options. Their focus is on advancing next-generation therapies that can set new standards of care across various health conditions. The company is committed to engaging ethically with patients, caregivers, and healthcare providers to address underserved needs. Elevar Therapeutics emphasizes collaboration within its skilled team to transform challenges into opportunities for the patients they serve.Explore more
Elevar Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Elevar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Elevar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Elevar Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Elevar Therapeutics
Website visits: Recent activity has been detected on your website
Check out if Elevar Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Elevar Therapeutics recently announced quarterly report
Product Launch: Get notified when Elevar Therapeutics launches new products
Check if Elevar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Elevar Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Elevar Therapeutics
Compare insights from companies similar to Elevar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
Elevar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Elevar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Elevar Therapeutics.
Elevar Therapeutics financials insights
Gather financial insights about Elevar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2021
Debt
$780K
Elevar Therapeutics Tech Stack
A closer look at the technologies used by Elevar Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves
Lateral Move
Executive Move
Executive Moves, Lateral Move
Open Position
Open Position
Elevar Therapeutics News & Media
Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
FORT LEE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the first patients were dosed in its global Phase 2 study of lirafugratinib in non-cholangiocarcinoma (CCA) solid tumors with FGFR2 fusion or rearrangement.Elevar Therapeutics Announces FDA Acceptance for Review of New Drug Application for Lirafugratinib as Second-line Cholangiocarcinoma Treatment
Fort Lee, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review of the New Drug Application (NDA) for lirafugratinib, an investigational therapy, for the treatment of patieElevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
FDA sets PDUFA target action date of July 23, 2026 FDA sets PDUFA target action date of July 23, 2026Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy
Former CEO Dr. Bryan Kim will retain current role as CEO of Verismo Therapeutics Former CEO Dr. Bryan Kim will retain current role as CEO of Verismo Therapeutics
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elevar Therapeutics
Sign Up For FreeTo access detailed company insights
Elevar Therapeutics is a biopharmaceutical company dedicated to developing oncology therapeutics aimed at improving treatment experiences and outcomes for patients with limited options. Their focus is on advancing next-generation therapies that can set new standards of care across various health conditions. The company is committed to engaging ethi... Read More
